SYNERGENE THERAPEUTICS, INC.;GEORGETOWN UNIVERSITY
发明人:
Esther H. Chang,Joe B. Harford,Sang Soo Kim
申请号：
US16597861
公开号：
US20200113829A1
申请日:
2019.10.10
申请国别(地区):
US
年份:
2020
代理人:
摘要：
This invention provides methods to overcome the current limitations of immune checkpoint immunotherapy to provide more effective methods of treating cancer. In embodiments this invention provides a means of using of p53 gene therapy to augment immune checkpoint inhibition by combining antibodies targeting immune checkpoint molecules with SGT-53, a nanomedicine carrying a plasmid encoding human wild-type p53. This invention provides means of increasing tumor immunogenicity, enhancing both innate and adaptive immune responses, and reducing tumor-induced immunosuppression, sensitizing otherwise refractory tumors to anti-immune checkpoint antibodies. In other embodiments this invention also unexpectedly reduces immune-related toxicities that are seen with immunotherapies.
